RenovoRx (Nasdaq:RNXT) announced today that it appointed Leesa Gentry as senior vice president of clinical operations. Los Altos, California-based RenovoRx said Gentry brings with her “valuable leadership experience” to advance the company’s cancer treatment studies. She becomes the fourth addition to the company’s executive management team in the last year. That group includes COO Angela […]
RenovoRx
Study supports RenovoRx drug-device combo for treating pancreatic cancer
RenovoRx (Nasdaq:RNXT) today announced promising interim data for its RenovoGem drug-device combination for treating pancreatic cancer. The Tiger-Pac clinical trial investigates RenovoGem as a potential treatment option in locally advanced pancreatic cancer (LAPC). Interim data from the Phase III open-label study suggests a six-month potential improvement in median overall survival with RenovoGem. RenovoGem utilizes the […]
RenovoRx wins FDA clearance for RenovoCath delivery system
RenovoRx today said it received FDA 510(k) clearance for its RenovoCath delivery system. Los Altos, California-based RenovoRx designed the RenovoCath system as the device component for its RenovoGem chemotherapy drug. The combined drug/device RenovoTAMP trans-arterial micro-perfusion therapy is a dual-balloon infusion catheter that delivers chemotherapy directly to tumors through the arteries. Get the full story […]
RenovoRx sets its sights on localized treatment of pancreatic cancer
People living with pancreatic cancer find themselves facing devastating odds – the five-year survival rate is in the single digits, according to the American Cancer Rate. Pursuing treatment often means dealing with the side effects of systemic chemotherapy, including hair loss, fatigue and neuropathy. Shaun Bagai and his team at RenovoRx think that their catheter could help […]
RenovoRx raises $7m for drug-device pancreatic cancer therapy
RenovoRx said today that it closed a $7 million tranche in a $10 million round to fund the development of its drug-device combination product designed to deliver chemotherapy directly to tumors in patients with locally advanced pancreatic cancer. The company’s round was led by Boston Scientific (NYSE:BSX) and joined by btov Partners, Astia Angels, Golden Seeds and others. […]
RenovoRx wins label expansion for RenovoCath device
RenovoRx said yesterday that it won label expansion for the RenovoCath dual-balloon infusion catheter to include the delivery of chemotherapeutics. The device isolates segments of the peripheral vasculature, allowing doctors to deliver therapeutics in a more targeted fashion, according to the Los Altos, Calif.-based company. “This additional FDA indication marks yet another milestone for RenovoRx as […]
Lessons Learned from Building the Renal Denervation Market with Ardian: Interview with Shaun Bagai, CEO of RenovoRx
Welcome to the Medsider interview series, a regular feature at MassDevice. All interviews are conducted by Scott Nelson, Founder of Medsider and Group Director for WCG. We hope you enjoy them! Shaun Bagai is the CEO of RenovoRx. He has over 16 years of medtech experience across multiple functional areas like clinical research, sales, marketing, and market development. […]
Predictive Technology Group closes Renovo buyout, names new prez
Salt Lake City, Utah-based Predictive Technology Group (OTCMKTS:PRED) said today it closed its buy of ReNovo Biotech and tapped former ReNovo Biotech CEO Eric Olson as the new prez of Predictive Biotech. Predictive Biotech said the acquisition will allow it access to ReNovo’s cellular, tissue, biomaterial and regenerative medicine products, as well as access to its […]
Ex-Stryker CFO Hartman wins CEO job at ConMed | Personnel Moves
RenovoRx raises over $1M Series B round
RenovoRx closed its Series B financing round, bringing in about $1.2 million for the catheter maker.
The San Jose, Calif.-based medical device company is working on catheter technology that directly delivers fluids to the peripheral vascular system. The financing round was led by angel funding group Golden Seeds, alongside the Angels’ Forum, Astia Angels and Amidzad Partners.
